Skip to main content
Conference Highlights ASH
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
Wayne Kuznar
Read More
Conference Highlights ASH
Improving the Standard of Care
R. Donald Harvey, PharmD, FCCP, BCOP
Read More
Conference Highlights ASH
Real-World Data on Primary Treatment for Mantle-Cell Lymphoma 2000-2011 – A Nordic Lymphoma Group Observational Study
Read More
Conference Highlights ASH
Oral Arsenic Trioxide-Based Regimen as Salvage Treatment for Relapsed or Refractory Mantle-Cell Lymphoma
Read More
Conference Highlights ASH
Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma in Need of Palliative Therapy
Read More
Conference Highlights ASH
The Single-Agent BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Responses Observed In All Mantle-Cell Lymphoma Patients
Read More
Conference Highlights ASH
Rituximab Maintenance Therapy after Autologous Stem-Cell Transplantation Prolongs Progression- Free Survival in Patients with Mantle-Cell Lymphoma
Read More
Conference Highlights ASH
Ibrutinib Overcomes Carfilzomib Resistance in Immunoproteasome-Deficient Mantle-Cell Lymphoma
Read More
Conference Highlights ASH
The RiBVD Regimen Offers a High Complete Response Rate in Elderly Patients with Untreated Mantle- Cell Lymphoma. Preliminary Results of the LYSA Trial “Lymphome Du Manteau 2010 SA”
Read More
Conference Highlights ASH
Lenalidomide, Bendamustine, and Rituximab as First-Line Therapy for Patients >65 Years with Mantle-Cell Lymphoma: Preliminary Results from the Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase 1-2 Trial
Read More
Page 1 of 4
Results 1 - 10 of 35